Evotec/$EVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evotec
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Ticker
$EVO
Sector
Primary listing
Employees
4,526
Headquarters
Website
Evotec Metrics
BasicAdvanced
$993m
-
-$1.24
1.30
-
Price and volume
Market cap
$993m
Beta
1.3
52-week high
$4.42
52-week low
$2.31
Average daily volume
35k
Financial strength
Current ratio
1.68
Quick ratio
1.445
Long term debt to equity
42.716
Total debt to equity
55.382
Interest coverage (TTM)
-512.13%
Profitability
EBITDA (TTM)
-18.998
Gross margin (TTM)
10.66%
Net profit margin (TTM)
-26.02%
Operating margin (TTM)
-12.10%
Effective tax rate (TTM)
-8.25%
Revenue per employee (TTM)
$182,130
Management effectiveness
Return on assets (TTM)
-3.14%
Return on equity (TTM)
-24.06%
Valuation
Price to revenue (TTM)
0.574
Price to book
1.25
Price to tangible book (TTM)
2.21
Price to free cash flow (TTM)
-8.087
Free cash flow yield (TTM)
-12.37%
Free cash flow per share (TTM)
-0.339
Growth
Revenue change (TTM)
-5.48%
Earnings per share change (TTM)
-6.78%
3-year revenue growth (CAGR)
-2.36%
10-year revenue growth (CAGR)
17.90%
3-year earnings per share growth (CAGR)
18.36%
10-year earnings per share growth (CAGR)
24.92%
What the Analysts think about Evotec
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Evotec Financial Performance
Revenues and expenses
Evotec Earnings Performance
Company profitability
Evotec News
AllArticlesVideos
Evotec Appoints Rui Wang as Head of Global In Silico and AI
Accesswire·4 weeks ago
Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Accesswire·1 month ago
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs